October 11, 2016 / 11:02 AM / 9 months ago

BRIEF-Auris Medical Holding AG provides update on its treatment for acute inner ear tinnitus

1 Min Read

Oct 11 (Reuters) - Auris Medical Holding AG :

* Auris Medical provides update on development of Keyzilen for the treatment of acute inner ear tinnitus

* based on insights from TACTT2 trial, submitting protocol amendment to regulatory agencies in Europe for TACTT3

* expects enrollment to resume in early 2017; top-line results from the expanded TACTT3 trial are now expected in early 2018

* says outcomes from TACTT2 and regulatory path forward will be reviewed with US FDA in early December 2016

* "disappointed that the TACTT2 trial failed to confirm the efficacy of keyzilen in the overall study population" Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below